Dr. Jhansi L. Koduri
Claim this profileMiami Valley Hospital South
Studies Breast Cancer
Studies Breast cancer
7 reported clinical trials
21 drugs studied
Area of expertise
1Breast Cancer
HER2 negative
PR positive
ER positive
2Breast Cancer
HER2 negative
PR positive
ER positive
Affiliated Hospitals
Clinical Trials Jhansi L. Koduri is currently running
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
More about Jhansi L. Koduri
Clinical Trial Related2 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Jhansi L. Koduri has experience with
- Pembrolizumab
- Biospecimen Collection
- Paclitaxel
- Cyclophosphamide
- Doxorubicin
- Standard Of Care Adjuvant Breast Radiation
Breakdown of trials Jhansi L. Koduri has run
Breast Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jhansi L. Koduri specialize in?
Jhansi L. Koduri focuses on Breast Cancer and Breast cancer. In particular, much of their work with Breast Cancer has involved HER2 negative patients, or patients who are PR positive.
Is Jhansi L. Koduri currently recruiting for clinical trials?
Yes, Jhansi L. Koduri is currently recruiting for 5 clinical trials in Centerville Ohio. If you're interested in participating, you should apply.
Are there any treatments that Jhansi L. Koduri has studied deeply?
Yes, Jhansi L. Koduri has studied treatments such as Pembrolizumab, Biospecimen Collection, Paclitaxel.
What is the best way to schedule an appointment with Jhansi L. Koduri?
Apply for one of the trials that Jhansi L. Koduri is conducting.
What is the office address of Jhansi L. Koduri?
The office of Jhansi L. Koduri is located at: Miami Valley Hospital South, Centerville, Ohio 45459 United States. This is the address for their practice at the Miami Valley Hospital South.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.